Insider Selling: AtriCure (NASDAQ:ATRC) Insider Sells $458,099.30 in Stock

AtriCure, Inc. (NASDAQ:ATRC) insider Karl Dahlquist sold 9,370 shares of the firm’s stock in a transaction that occurred on Monday, August 24th. The shares were sold at an average price of $48.89, for a total transaction of $458,099.30. Following the completion of the transaction, the insider directly owned 87,319 shares of the company’s stock, valued at approximately $4,269,025.91. The trade was a 9.69% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

AtriCure Trading Down 1.5%

Shares of ATRC stock opened at $48.54 on Friday. AtriCure, Inc. has a fifty-two week low of $25.36 and a fifty-two week high of $49.98. The company has a 50 day moving average price of $37.89 and a 200 day moving average price of $32.26. The stock has a market capitalization of $2.47 billion, a P/E ratio of 231.15 and a beta of 1.20. The company has a debt-to-equity ratio of 0.14, a quick ratio of 3.19 and a current ratio of 4.22.

AtriCure (NASDAQ:ATRC) last released its earnings results on Thursday, July 23rd. The medical device company reported $0.18 earnings per share (EPS) for the quarter. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. The company had revenue of $153.60 million for the quarter, compared to analyst estimates of $151.80 million. During the same period in the prior year, the business earned ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. Equities research analysts predict that AtriCure, Inc. will post 0.29 EPS for the current fiscal year.

Hedge Funds Weigh In On AtriCure

A number of institutional investors and hedge funds have recently modified their holdings of ATRC. Smartleaf Asset Management LLC raised its stake in AtriCure by 59.8% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,146 shares of the medical device company’s stock valued at $46,000 after buying an additional 429 shares in the last quarter. Scotia Capital Inc. lifted its holdings in AtriCure by 1.2% during the 3rd quarter. Scotia Capital Inc. now owns 37,677 shares of the medical device company’s stock worth $1,328,000 after buying an additional 457 shares during the last quarter. ProShare Advisors LLC boosted its position in shares of AtriCure by 6.6% during the 4th quarter. ProShare Advisors LLC now owns 8,819 shares of the medical device company’s stock worth $349,000 after acquiring an additional 543 shares in the last quarter. Captrust Financial Advisors increased its holdings in shares of AtriCure by 7.9% in the 4th quarter. Captrust Financial Advisors now owns 7,944 shares of the medical device company’s stock valued at $314,000 after acquiring an additional 579 shares during the last quarter. Finally, Mackenzie Financial Corp increased its holdings in shares of AtriCure by 5.3% in the 4th quarter. Mackenzie Financial Corp now owns 13,597 shares of the medical device company’s stock valued at $545,000 after acquiring an additional 683 shares during the last quarter. Institutional investors and hedge funds own 99.11% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on ATRC shares. Zacks Research lowered AtriCure from a “strong-buy” rating to a “hold” rating in a report on Monday, August 24th. BTIG Research upped their price target on AtriCure from $45.00 to $55.00 and gave the stock a “buy” rating in a report on Monday, August 24th. Piper Sandler increased their price target on AtriCure from $50.00 to $60.00 and gave the company an “overweight” rating in a research report on Thursday. Canaccord Genuity Group lifted their price objective on AtriCure from $53.00 to $55.00 and gave the company a “buy” rating in a research note on Wednesday, May 6th. Finally, Wall Street Zen downgraded AtriCure from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 2nd. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $49.89.

AtriCure Company Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.